Division of Urology, Children's National Medical Center, Washington, DC, 20010, USA.
Department of Radiology, Children's National Medical Center, Washington, DC, 20010, USA.
J Pediatr Urol. 2024 Oct;20(5):921-928. doi: 10.1016/j.jpurol.2024.06.011. Epub 2024 Jun 19.
Hydronephrosis grading systems risk stratify patients with potential ureteropelvic junction obstruction, but only some criteria are measured objectively. Most notably, there is no consensus definition of renal parenchymal thinning.
The objective of this study was to assess the association between sonographic measures of renal length, renal pelvic diameter, and renal parenchymal thickness and the outcomes of a)renal hypofunction(differential renal function{DRF} <40%) and b)high-risk renal drainage(T1/2 > 40 min).
An institutional database of patients who had diuretic renograms(DR) for unilateral hydronephrosis was reviewed. Only infants with Society for Fetal Urology(SFU) grades 3/4 hydronephrosis without hydroureter on postnatal sonogram and had a DR within 120 days were included. The following measurement variables were analyzed: anterior posterior renal pelvic diameter(APRPD), renal length(RL), renal parenchymal thickness(PT), minimal renal parenchymal thickness(MPT = shortest distance from mid-pole calyx to parenchymal edge), and renal pyramidal thickness(PyrT). RL, PT, MPT, PyrT measurements were expressed as ratios (hydronephrotic kidney/contralateral kidney). Multivariate logistic regression was performed for each outcome by comparing three separate renal measurement models. Model 1: RLR, APRPD, MPTR; Model 2: RLR, APRPD, PTR, Model 3: RLR, APRPD, PyrTR. Individual performance of variables from the best performing model were assessed via ROC curve analysis.
196 patients were included (107 with SFU grade 3, 89 with SFU grade 4) hydronephrosis. Median patient age was 29[IQR 16,47.2] days. 10% had hypofunction, and 20% had T1/2 > 40 min 90% with hypofunction and 87% with high-risk drainage had SFU4 hydronephrosis. Model 1 exhibited the best performance, but on multivariate analysis, only APRPD and MPTR were independently associated with both outcomes. No other measure of parenchymal thickness reached statistical significance. The odds of hypofunction and high-risk drainage increase 10% per 1 mm increase in APRPD(aOR 1.1 [CI 1.03-1.2], p = 0.005; aOR 1.1 [CI 1.03-1.2], p = 0.003). For every 0.1unit increase in MPTR the odds of hypofunction decrease by 40%(aOR 0.6 [CI 0.4-0.9], p = 0.019); and the odds of high-risk drainage decrease by 30%(aOR 0.7 [CI 0.5-0.9], p = 0.011). Optimal statistical cut-points of APRPD >16 mm and/or MPTR <0.36 identified patients at risk for obstructive parameters on DR.
Of the sonographic hydronephrosis measurement variables analyzed, only APRPD and MPTR were independently associated with objective definitions of obstruction based on renal function and drainage categories. Patients who maintain APRPD <16 mm and/or MPTR >0.36 can potentially be monitored with renal sonograms as there is >90% chance that they will not have DRF<40% or T1/2 > 40 min.
肾积水分级系统对有潜在肾盂输尿管连接部梗阻的患者进行风险分层,但只有部分标准是客观测量的。最值得注意的是,目前还没有关于肾实质变薄的共识定义。
本研究的目的是评估超声测量的肾长度、肾盂直径和肾实质厚度与以下结果之间的关系:a)肾功能减退(肾小球滤过率[DRF]<40%)和 b)高危肾引流(T1/2>40 分钟)。
对有单侧肾积水的利尿剂肾图(DR)的机构数据库进行了回顾。仅纳入 SFU 分级 3/4 级肾积水且在出生后超声检查中无肾盂扩张且在 120 天内进行 DR 的婴儿。分析了以下测量变量:前后肾盂直径(APRPD)、肾长度(RL)、肾实质厚度(PT)、最小肾实质厚度(MPT=最短距离从中极肾盏到实质边缘)和肾锥体厚度(PyrT)。RL、PT、MPT、PyrT 测量值表示为(积水肾/对侧肾)的比值。通过比较三种不同的肾脏测量模型,对每种结果进行多元逻辑回归分析。模型 1:RLR、APRPD、MPTR;模型 2:RLR、APRPD、PTR;模型 3:RLR、APRPD、PyrTR。通过 ROC 曲线分析评估最佳模型中各变量的个体性能。
共纳入 196 例患者(107 例 SFU 分级 3 级,89 例 SFU 分级 4 级)。中位患者年龄为 29[IQR 16,47.2]天。10%的患者有肾功能减退,20%的患者 T1/2>40 分钟,90%有肾功能减退和 87%有高危引流的患者有 SFU4 级肾积水。模型 1 表现最佳,但在多变量分析中,只有 APRPD 和 MPTR 与两种结果独立相关。其他肾实质厚度测量值均未达到统计学意义。APRPD 每增加 1 毫米,肾功能减退和高危引流的几率增加 10%(优势比[OR]1.1[95%CI 1.03-1.2],p=0.005;OR 1.1[95%CI 1.03-1.2],p=0.003)。MPTR 每增加 0.1 单位,肾功能减退的几率降低 40%(OR 0.6[95%CI 0.4-0.9],p=0.019);高危引流的几率降低 30%(OR 0.7[95%CI 0.5-0.9],p=0.011)。APRPD>16 毫米和/或 MPTR<0.36 的最佳统计学切点可识别出 DR 上存在梗阻参数风险的患者。
在所分析的超声肾积水测量变量中,只有 APRPD 和 MPTR 与基于肾功能和引流类别的梗阻的客观定义独立相关。保持 APRPD<16 毫米和/或 MPTR>0.36 的患者可以通过肾脏超声进行监测,因为他们有>90%的机会不会出现 DRF<40%或 T1/2>40 分钟。